Article Text
PDF
Abstract
Objective Determine longitudinal tobacco product discontinuation rates among youth (ages 12–17 years) in the USA between 2013 and 2019.
Methods The Population Assessment of Tobacco and Health Study, a nationally representative, longitudinal cohort study, was used to determine annual/biennial rates of tobacco product discontinuation behaviours among youth across 2013–2019: (1) discontinuing product use (transition from past 30-day use to no past 30-day use), (2) attempting to quit product use and (3) discontinuing product use among those who attempted to quit. Discontinuing use was evaluated separately for cigarettes, electronic nicotine delivery systems (ENDS), cigars, hookah, smokeless tobacco and any tobacco. Attempting to quit and discontinuing use among those who attempted were each evaluated for cigarettes and ENDS. Generalised estimating equations were used to evaluate linear and non-linear trends in rates across the study period.
Results Between 2013 and 2019, biennial rates of discontinuing tobacco product use among youth increased for cigarettes from 29% to 40%, increased for smokeless tobacco from 39% to 60%, and decreased for ENDS from 53% to 27%. By 2018/2019, rates of discontinuing use among attempters were 30% for those who used ENDS and 30% for those who smoked cigarettes.
Conclusions Findings show decreasing rates of discontinuing ENDS use among youth in the USA alongside the changing ENDS marketplace and increasing rates of discontinuing cigarette smoking and smokeless tobacco use. Findings will serve as benchmarks against which future tobacco product discontinuation rates can be compared with evaluating impacts of subsequent tobacco regulatory policies, ENDS product development and public education campaigns.
- Cessation
- Electronic nicotine delivery devices
- Non-cigarette tobacco products
- Prevention
- Surveillance and monitoring
Data availability statement
Data from the Population Assessment of Tobacco and Health Study waves 1-5 may be obtained from a third party and are not publicly available (https://www.icpsr.umich.edu/icpsrweb/NAHDAP/studies/36231). Application instructions and conditions of use are available at the website mentioned.
Statistics from Altmetric.com
- Cessation
- Electronic nicotine delivery devices
- Non-cigarette tobacco products
- Prevention
- Surveillance and monitoring
Data availability statement
Data from the Population Assessment of Tobacco and Health Study waves 1-5 may be obtained from a third party and are not publicly available (https://www.icpsr.umich.edu/icpsrweb/NAHDAP/studies/36231). Application instructions and conditions of use are available at the website mentioned.
Footnotes
Contributors KAK, ZT and AH led the conceptual design of the work. KAK drafted the initial manuscript and all authors critically revised it. ZT conducted the statistical analysis. KAK and AH serve as guarantors of the work. All authors contributed to the interpretation of results, approved the work for journal publication and agreed to be accountable for all aspects of the work. This article was prepared while JV was employed at the Food and Drug Administration, Center for Tobacco Products.
Funding This manuscript is supported with Federal funds from the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA), Department of Health and Human Services, under contract to Westat (contract nos. HHSN271201100027C and HHSN271201600001C), and through an interagency agreement between NIH NIDA and FDA CTP. Daniela Marshall was substantially involved in the scientific management of and providing scientific expertise for contract nos. HHSN271201100027C and HHSN271201600001C.
Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Department of Health and Human Services or any of its affiliated institutions or agencies.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.